Arcellx, Inc. (ACLX)
Data as of , from SEC Form 4 filings.
See up to 3 months of ACLX. The 7-day demo opens the 1M and 3M ranges and puts ACLX on your watchlist.
Start 7-day demoLatest ACLX insider trades
- Rami Elghandour - OfficerOpen-market sale$10.24M
Michelle Gilson - OfficerOpen-market sale$1.28M
About Arcellx, Inc. (ACLX)
Arcellx, Inc. files with the SEC under CIK 0001786205 and is classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
ACLX Form 4 activity by transaction type, last 90 days
No Form 4 activity for ACLX in the last 90 days.
ACLX insider transactions (Form 4)
5142 Form 4 filings on record, the earliest from Oct 3, 2024, newest first. Filing history page 2 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christopher Heery - Officer | Open-market sale | Common Stock | 12,396 | $80.12 | $993K | |
| Christopher Heery - Officer | Open-market sale | Common Stock | 3,343 | $80.01 | $267K | |
| Christopher Heery - Officer | Open-market sale | Common Stock | 300 | $80.00 | $24K | |
| Rami Elghandour - Officer | Tax withholding / forfeiture | Common Stock | 546,938 | $70.25 | $38.42M | |
 Ali Behbahani | Other | Common Stock | 1,586 | $0.00 | - | |
| Ali Behbahani | Other | Common Stock | 2,621 | $0.00 | - | |
| Kavita Patel | Option exercise | Common Stock | 1,500 | $6.66 | $10K | |
| Kavita Patel | Open-market sale | Common Stock | 1,400 | $76.92 | $108K | |
| Kavita Patel | Open-market sale | Common Stock | 100 | $77.61 | $8K | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Kavita Patel | Option exercise | Common Stock | 1,500 | $6.66 | $10K | |
| Kavita Patel | Open-market sale | Common Stock | 300 | $88.53 | $27K | |
| Kavita Patel | Open-market sale | Common Stock | 400 | $89.84 | $36K | |
| Kavita Patel | Open-market sale | Common Stock | 200 | $91.91 | $18K | |
| Kavita Patel | Open-market sale | Common Stock | 300 | $93.76 | $28K | |
| Kavita Patel | Open-market sale | Common Stock | 300 | $96.05 | $29K | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 1,061 | $87.89 | $93K | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 500 | $89.17 | $45K | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 100 | $91.67 | $9K | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 100 | $95.00 | $10K | |
| Michelle Gilson - Officer | Option exercise | Common Stock | 3,000 | $8.66 | $26K | |
| Michelle Gilson - Officer | Option exercise | Stock Option (right to buy) | 3,000 | $0.00 | - | |
| Kavita Patel | Option exercise | Common Stock | 1,500 | $6.66 | $10K | |
| Kavita Patel | Open-market sale | Common Stock | 1,500 | $106.33 | $159K | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Michelle Gilson - Officer | Option exercise | Common Stock | 7,200 | $8.66 | $62K | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 9,700 | $100.26 | $973K | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 1,853 | $101.27 | $188K | |
| Michelle Gilson - Officer | Open-market sale | Common Stock | 801 | $102.33 | $82K | |
| Michelle Gilson - Officer | Option exercise | Stock Option (right to buy) | 7,200 | $0.00 | - | |
| Kavita Patel | Option exercise | Common Stock | 8,478 | $6.66 | $56K | |
| Kavita Patel | Open-market sale | Common Stock | 8,478 | $99.30 | $842K | |
| Kavita Patel | Option exercise | Common Stock | 7,976 | $6.66 | $53K | |
| Kavita Patel | Option exercise | Common Stock | 25,787 | $15.00 | $387K | |
| Kavita Patel | Open-market sale | Common Stock | 5,900 | $99.60 | $588K | |
| Kavita Patel | Open-market sale | Common Stock | 2,076 | $100.57 | $209K | |
| Kavita Patel | Open-market sale | Common Stock | 25,787 | $105.46 | $2.72M | |
| Kavita Patel | Option exercise | Common Stock | 15,238 | $15.00 | $229K | |
| Kavita Patel | Open-market sale | Common Stock | 12,233 | $105.68 | $1.29M | |
| Kavita Patel | Open-market sale | Common Stock | 3,005 | $106.91 | $321K | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 8,478 | $0.00 | - | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 7,976 | $0.00 | - | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 25,787 | $0.00 | - | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 15,238 | $0.00 | - | |
| Kavita Patel | Option exercise | Common Stock | 1,500 | $6.66 | $10K | |
| Kavita Patel | Open-market sale | Common Stock | 1,500 | $89.69 | $135K | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - | |
| Kavita Patel | Option exercise | Common Stock | 1,500 | $6.66 | $10K | |
| Kavita Patel | Open-market sale | Common Stock | 1,500 | $82.24 | $123K | |
| Kavita Patel | Option exercise | Stock Option (right to buy) | 1,500 | $0.00 | - |
ACLX insider trading FAQ
What is the latest insider trade for ACLX?
Arcellx, Inc. (ACLX) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-04-28. The full record for ACLX runs to 42 Form 4 filings, the earliest from 2024-10-03. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying ACLX stock?
No insider purchases of ACLX were filed in the last 90 days.
How many insiders are selling ACLX stock?
No insider sales of ACLX were filed in the last 90 days. 45 sales are on record for this company.
Where can I see ACLX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects ACLX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Jill Carroll view on EDGAR
- - Ali Behbahani view on EDGAR
- - Olivia C. Ware view on EDGAR
- - Kavita Patel view on EDGAR
- - Kristin Myers view on EDGAR
- - David Charles Lubner view on EDGAR
- - Andrew H. Galligan view on EDGAR
- - Michelle Gilson view on EDGAR
- - Christopher Heery view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where ACLX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow ACLX with a 7-day demo
- ACLX on your watchlist
- Every ACLX Form 4 filing on record
- Up to 3 months of ACLX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
